FDA (CDRH)
GUIDANCE DRAFT
Menstrual Products - Performance Testing and Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff
Published: 10/28/2025Detected: 3/25/2026
Summary preview
Outlines FDA’s draft approach for premarket performance testing and labeling for menstrual products, which may affect how sponsors design validation studies and structure product claims.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#menstrual products
#performance testing
#premarket
#labeling
#validation
Official Source Document Source Verified
Access the original document directly from FDA CDRH.
More from FDA (CDRH)
- Robotically-Assisted Surgical Devices - Premarket Submissions: Draft Guidance for Industry and Food and Drug Administration Staff9/25/2026
- Electronic Submission Template for Premarket Approval Applications (PMA): Draft Guidance for Industry and Food and Drug Administration Staff9/18/2026
- Dental Curing Lights - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff9/2/2026
- Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Guidance for Industry and Food and Drug Administration Staff9/2/2026
- Applying Human Factors and Usability Engineering to Medical Devices: Guidance for Industry and Food and Drug Administration Staff8/3/2026